Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1987 and is headquartered in New York, New York.

Period	fcf
2015-12-31	-$16.41M
2016-12-31	-$15.56M
2017-12-31	-$15.92M
2018-12-31	-$14.81M
2019-12-31	-$23.71M
2020-12-31	-$23.65M
2021-12-31	-$22.75M
2022-12-31	-$25.16M
2023-12-31	-$31.31M
2024-12-31	-$18.70M

	A	B	C	D
1	Symbol	Price	Change	Volume
2	DCTH	$9.63	+0.00%	0.29M
3
4
5

Delcath Systems Inc. (DCTH) Free Cash Flow

Free Cash Flow Data

Get Delcath Systems Inc. Data in Excel

More DCTH Financial Data